Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 12:43 AM
Ignite Modification Date: 2025-12-25 @ 12:43 AM
NCT ID: NCT06821867
Eligibility Criteria: Inclusion Criteria: 1. Subject Informed consent form (ICF) signed; 2. Female and male Subjects aged 18-70 years; 3. Subjects desiring improvement of skin hydration in maximum 2 areas of the face, or 1 area of the face plus neck or décolleté; 4. Healthy skin; 5. Willingness to discontinue all dermatological treatment and procedures during the study; 6. Willingness to follow all study procedures, including attending all site visits, tests and examinations; 7. Agreeing to present at each study visit without face/neck/ décolleté cosmetics; 8. Accepting to not change their habits regarding food, physical activity, face/neck/décolleté cosmetics and cleansing products; 9. Willingness to follow indications to minimize exposure of the treated area to too much sunlight or extreme cold, at least until the papules have completely subsided; 10. Skin phototype I-IV according to Fitzpatrick's classification. Exclusion Criteria: 1. Other - different - clinical conditions of the skin (i.e. rosacea, psoriasis, vitiligo, active eczema, severe scleroderma, severe acne and diagnosticated cancer with/without ongoing antitumor therapy); 2. Infectious or inflammatory processes near the area of intervention; 3. Presence of cutaneous disease on the tested area, as malformations and recurrent facial/labial herpes; 4. Presence of tendon, bone or muscular implants near the area of intervention; 5. Ongoing cutaneous allergies; 6. Allergy or contraindications to device components; 7. Concomitant intake of anticoagulant or antiplatelet medications; 8. Subjects who have not followed a washout period of 2 weeks from topical corticosteroids, antibiotics, benzoyl-peroxide, azelaic acid, hydroxy acids, topical retinoids; 9. Immune system illnesses/disease; 10. Uncontrolled diabetes mellitus or uncontrolled systemic diseases (endocrine, hepatic renal, cardiac, pulmonary, neurological disorder); 11. Treatment with substances which act on blood fluidity (eg. Aspirin, NSAIDs, Vitamin E), or drugs able to influence the test results in the investigator opinion, within 5 days prior to study inclusion; 12. Known drug and/or alcohol abuse; 13. Mental incapacity that precludes adequate understanding or cooperation; 14. Any previous permanent and non-permanent cutaneous treatment for aesthetic correction (biomaterial implant, lifting, laser, botulinum toxin injections, chemical peeling, fillers) of the treated area within 6 months prior to study inclusion; 15. Pregnancy or breastfeeding; 16. Participation in another investigational study within 1 month prior to study inclusion.
Healthy Volunteers: True
Sex: ALL
Minimum Age: 18 Years
Study: NCT06821867
Study Brief:
Protocol Section: NCT06821867